Background: Although randomized trials demonstrate the noninferiority of rivaroxaban compared with warfarin in the context of nonvalvular atrial fibrillation (AF), little is known about how these drugs compare in practice. Objective: To assess the relative effectiveness and safety of rivaroxaban versus warfarin in a large health system and to evaluate this association by time in therapeutic range (TTR). Methods: We conducted a retrospective cohort study with propensity matching in the Cleveland Clinic Health System. The study included patients initiated on warfarin or rivaroxaban for thromboembolic prevention in nonvalvular AF between January 2012 and July 2016. The main outcomes were thromboembolic events and major bleeds. Analyses were stratified by warfarin patients' TTR. Results: The cohort consisted of 472 propensitymatched pairs. The mean age was 73.6 years (SD = 11.7), and the mean CHADS 2 score was 1.8. The median TTR for warfarin patients was 64%. In the propensity-matched analysis, there was no significant difference in thromboembolic or major bleeding events between groups. Among warfarin patients with a TTR <64% and their matched rivaroxaban pairs, there was also no significant difference in thromboembolic or major bleeding events. Conclusions: Under realworld conditions, warfarin and rivaroxaban were associated with similar safety and effectiveness, even among those with suboptimal therapeutic control. Individualized decision making, taking into account the nontherapeutic tradeoffs associated with these medications (eg, monitoring, half-life, cost) is warranted.
Background
Anticoagulation is widely used to prevent thromboembolic events in individuals with atrial fibrillation (AF). 1 Although efficacious, anticoagulation is also associated with an increased risk of bleeding that can be life threatening or fatal. 2 As a result, physicians must balance the predicted benefits and potential harms when prescribing anticoagulation. 3 Warfarin is an oral vitamin-K antagonist anticoagulant that has been widely used for more than 50 years. 4, 5 Frequent monitoring is necessary to ensure that patients maintain an international normalized ratio (INR) within the therapeutic range; also, warfarin has a number of drug-drug and drugfood interactions, which makes maintaining a therapeutic INR challenging. 6 Rivaroxaban is a direct oral anticoagulant (DOAC) that works by inhibiting clotting factor Xa. 7 In randomized controlled trials, rivaroxaban was found to be noninferior to warfarin for the prevention of stroke and systemic embolism in the setting of nonvalvular AF 1 as well as recurrent venous thromboembolism. 8, 9 In trials, rivaroxaban and warfarin pose similar risks of major bleeding, 1, [8] [9] [10] yet unlike warfarin, rivaroxaban does not require therapeutic monitoring and has minimal food and drug-drug interactions. As a result, prescriptions for rivaroxaban have increased steadily since Food and Drug Administration (FDA) approval in 2011. It is currently the most commonly prescribed DOAC 11 and is among the top 25 highest grossing pharmaceuticals worldwide. 12 Despite this popularity, use of rivaroxaban may be challenging in a real-world setting because of the lack of a therapeutic monitoring system or a reliable reversal agent. Rivaroxaban is also considerably more expensive than warfarin, which may have implications for patient drug adherence and persistence. 13, 14 A number of recent meta-analyses examining the efficacy and safety of DOACs relative to warfarin found that DOACs, including rivaroxaban, are safer and more efficacious in preventing systemic embolization than warfarin. [15] [16] [17] At the same time, doubts regarding the validity of the original ROCKET-AF trial findings, on which these meta-analyses are partially based, have recently surfaced. 18, 19 Studies examining the effectiveness and safety of rivaroxaban and warfarin in clinical practice are, therefore, critical to understanding the true balance of risks and benefits. 15 A recent systematic review and meta-analysis of such studies found that rivaroxaban was more effective than warfarin in preventing thromboembolic events and carried a similar risk of major bleeding. 20 However, all included studies relied on administrative data to evaluate study outcomes, which can be incomplete and subject to error. 21 Moreover, only 1 assessed time in therapeutic range (TTR) to assess whether the warfarin therapy was adequate. 22 Patients who struggle to stay in therapeutic range may have higher rates of major bleeding and thromboembolic events. For patients at risk of nonadherence, which is highly associated with lower TTR, 23 physicians may prefer to initiate rivaroxaban, believing it to be safer because it does not require therapeutic monitoring and has limited drug interactions. However, because of the shorter half-life of rivaroxaban, nonadherent patients may experience lower effectiveness as a result of missed doses. 24 Whereas prior studies have accounted for TTR among warfarin patients, no such measure exists for rivaroxaban. One prior study compared the safety and effectiveness of the drugs using administrative data by TTR using propensity-matched pairs. 22 However, INR data were available for <10% of their total sample. Furthermore, they were unable to validate events through medical record review. Thus, the relative safety and effectiveness of warfarin compared with rivaroxaban among those patients at risk of suboptimal therapeutic management on either drug remains undetermined.
Consequently, we conducted a retrospective cohort study to assess 4 years of experience with rivaroxaban versus warfarin for the prevention of stroke and systemic embolism in nonvalvular AF in one health system. Because we were specifically interested in understanding how these drugs compared among patients at risk of poor therapeutic control, we stratified our matched analysis by warfarin patients' TTR.
Methods

Study Design and Sample
We performed a retrospective cohort study within the Cleveland Clinic Health System (CCHS) between January 1, 2012, and July 1, 2016. The CCHS comprises 1 large academic medical center, 8 regional hospitals, 18 family health centers, and 18 outpatient primary care practices.
This study was approved by the institutional review board of the Cleveland Clinic. Eligible patients, identified from the electronic health record (EHR), included individuals 18 years or older initiated on warfarin or rivaroxaban for nonvalvular AF. Patients were excluded if they had had valve replacements, had active cancer, or did not have a CCHS office visit encounter before and after the study drug start date. Because we wanted to ensure that all patients were new to anticoagulation, we also excluded patients who had taken an anticoagulant within 2 years prior to the study start date. Additionally, warfarin patients were excluded if they did not have at least 4 INRs documented while on therapy. All patients were followed until therapy was discontinued or until the end of the study period. If a patient switched from warfarin to rivaroxaban or vice versa during the study period, that was considered discontinuation of the index drug, and they were censored at that time.
Assessment of Outcomes
Study outcomes were first ascertained via the EHR, which identified ICD-9 and ICD-10 codes associated with thromboembolic and major bleeding events. Because this approach is sensitive but not specific, we then confirmed all events through medical record review, conducted by 1 clinical pharmacist and 2 medical students (GR-A, AC, and CI). Reviewers were not blinded to the study drug. This manual chart review ensured that outcomes occurred while on anticoagulation therapy and met our definitions of thromboembolic and major bleeding events.
Effectiveness Measures
Our primary measure of effectiveness was thromboembolic events, defined as ischemic stroke, systemic embolism, pulmonary embolism, deep-vein thrombosis, or transient ischemic attack.
Safety Measures
Our primary measure of safety was major bleeding events. 25 A major bleeding event was defined in 2 ways: (1) any clinically overt sign of hemorrhage that required an intervention to stop or treat bleeding (including drug discontinuation) and that led to hospitalization, increased level of care, or an unscheduled visit to a health care professional, resulting in diagnostic testing, or (2) clinical, laboratory, and/or imaging evidence of overt bleeding plus a drop in hemoglobin ≥3 g/dL or transfusion with whole blood or packed red blood cells.
Rivaroxaban and Warfarin Dosing
Appropriateness of anticoagulant dosing was evaluated for each event that occurred while on therapy. For patients prescribed rivaroxaban, appropriate dosing was determined based on indication and renal function as outlined in the package insert.
Time in Therapeutic Range
We used warfarin patients' TTR as a measure of therapeutic control. Because poor warfarin adherence is highly associated with lower TTR, 23 we regarded lower TTR as an approximation of poor adherence. For warfarin patients, we identified the INR at the time of the event and calculated TTR throughout the study period using the Rosendaal method, 26 which adds each patient's time within the therapeutic range and divides by the total time of observation, assuming that the between-test INR varies linearly. INRs included both point-of-care testing and lab-based measures.
Demographic and Clinical Characteristics
Demographic characteristics were derived from the EHR and included patient age, sex, race, ethnicity, insurance status (private vs public), and income (based on median income by zip code). Baseline clinical characteristics were also derived from the EHR and included body mass index (BMI), creatinine clearance (using Cockcroft-Gault equation), 27 history of stroke, major bleeding, hypertension, diabetes, heart failure, vascular disease, and history of antiplatelet use prior to starting anticoagulation therapy.
Statistical Analysis
Rivaroxaban and warfarin patients were matched 1:1 based on propensity score using the nearest neighbor method. 28 Propensity matching is a statistical approach that can reduce the effects of confounding in observational studies by balancing treatment groups on key variables. Propensity model variables included age, sex, race, ethnicity, BMI, insurance status, income, creatinine clearance, 27 history of a stroke, major bleed, hypertension, diabetes, heart failure, vascular disease, and history of antiplatelet use.
Treatment groups were compared on demographic and medical history measures using linear and logistic regression models. Kaplan-Meier estimates of survival were created, and groups were compared using Cox proportional hazards models, adjusting for propensity score (to further ensure the score itself did not affect model outcomes). Because we were interested in evaluating whether the effectiveness and safety of the drugs varied by TTR, we stratified the aforementioned propensity-matched analysis at the median TTR of the warfarin patients. This allowed us to compare warfarin patients with lower or higher TTRs with their matched rivaroxaban counterparts, who we assumed would have similar therapeutic control. Analyses were performed using R software (version 3.1; Vienna, Austria).
Results
The sample included 472 rivaroxaban patients and 472 propensity-matched warfarin controls (n = 944). Table 1 shows the patient characteristics for all study participants. The mean age was 73.6 years (SD = 11.7 years); 62% were male; and 32% had private insurance. The mean BMI was 30.4 kg/m 2 , and 85% of patients had adequate renal function (creatinine clearance > 50 mL/min). The mean CHADS 2 score was 1.8. The mean number of INRs for warfarin patients during the study period was 33 (interquartile range = 13-47). Rivaroxaban and warfarin patients did not differ significantly in baseline characteristics for anticoagulation. Table 2 compares the event rates for thromboembolic and major bleeding events. Compared with patients on warfarin, those on rivaroxaban did not have significantly different rates of thromboembolic events (0.66 vs 1.32 per 100 patient-years; P = 0.25) or major bleeding events (1.21 vs 1.13 per 100 patient-years; P = 0.78).
The median TTR for the warfarin patients was 64.3%. The median durations of therapy were 9 months and 20 months for the rivaroxaban and warfarin groups, respectively, and this was a statistically significant difference (P < 0.001). However, when restricting the data to the 30 patients with an event, the median duration times did not differ significantly: 8.9 months and 8.3 months for the rivaroxaban and warfarin groups, respectively (P = 0.75).
A total of 29% (n = 2) of the rivaroxaban doses were too high at the time of a thromboembolic event, and 33% (n = 2) of the doses were too high at the time of a major bleeding event. All patients with inappropriate high doses were overdosed based on indication and renal function (eg, patients received 20 mg daily instead of 15 mg daily). For warfarin patients, 50% (n = 3) of the INRs were subtherapeutic at the time of the thromboembolic events, and 64% (n = 7) of the INRs were supratherapeutic at the time of the major bleeding events. One patient had a subtherapeutic INR at the time of a major bleeding event. Table 3 shows the event rates stratified at the median TTR (64.3%). For matched patients with TTRs ≥64.3%, there was no significant difference in thromboembolic events (0.75 per 100 patient-years for warfarin compared with 0.71 per 100 patient-years for rivaroxaban, P = 0.86) or major bleeding events (0.38 per 100 patient-years for warfarin compared with 1.07 per 100 patient-years for rivaroxaban, P = 0.36). For matched patients with median TTR <64.3%, there was also no significant difference in thromboembolic events (0.53 per 100 patient-years for warfarin compared with 2.02 per 100 patient-years for rivaroxaban, P = 0.12) or major bleeding events (2.39 per 100 patientyears for warfarin compared with 1.21 per 100 patient-years for rivaroxaban, P = 0.32).
Discussion
In this study of the effectiveness and safety of rivaroxaban versus warfarin in the real world, we found that the risk of thromboembolic and major bleeding events were similar. Rivaroxaban may be considered an attractive alternative to warfarin for those patients who find the routine therapeutic monitoring associated with warfarin to be challenging. That we found no difference in the safety or effectiveness of rivaroxaban and warfarin among patients with TTRs below the median suggests that rivaroxaban and warfarin are equally effective and safe for patients at risk of poor therapeutic control.
Randomized controlled trials provide information about the efficacy of different agents under optimal circumstances, yet their effectiveness-how they work in the "real world"-may differ from trial results. The rapid uptake of rivaroxaban for nonvalvular AF following FDA approval in 2011 11 was informed by results of the ROCKET-AF trial, which demonstrated rivaroxaban's noninferiority to warfarin for stroke and systemic embolism prevention in nonvalvular AF. 1 Our population was comparable with that of the ROCKET-AF trial, but our patients had a lower risk of stroke (CHADS 2 of 1.8 in our study vs 3.47 in ROCKET-AF). Patients in our study also had a lower burden of comorbidities.
A number of recent studies have evaluated the real-world effectiveness and safety of rivaroxaban versus warfarin using administrative or registry data. These studies have largely found that rivaroxaban was superior to warfarin for the prevention of thromboembolic events and was associated with similar rates of major bleeding. 20 Our study differs from other prior observational comparisons of the drugs because we did not rely on administrative codes alone to identify events. Confirmation of all events through medical record review allowed us to ensure that all events were true positives, which may explain our different finding of no difference in thromboembolic or major bleeding risk between the drugs.
Patients who are unable to maintain therapeutic INRs on warfarin because of nonadherence are also unlikely to optimally take their rivaroxaban. Propensity matching rivaroxaban patients with lower-TTR warfarin patients allowed us to evaluate a sample of rivaroxaban patients not well studied: patients unlikely to be optimally adherent to rivaroxaban. Only 1 prior study has stratified propensity-matched cohorts of rivaroxaban and warfarin patients by TTR. 29 The duration of follow-up was similar to that in our study, as was baseline thromboembolic risk in the study population. Likewise, they found a higher thromboembolic event rate among rivaroxaban patients compared with propensitymatched warfarin patients in the lower-TTR group; however, this difference was also not statistically significant. 30 Taken together, findings from this prior study and ours presented here support the need for a better understanding of the relative safety and effectiveness of rivaroxaban compared with warfarin among patients at risk for poor therapeutic control. This is particularly important given that the popularity of rivaroxaban continues to grow.
Drug discontinuation in the ROCKET-AF trial was low and similar for both drugs: 24% for rivaroxaban and 22% for warfarin. Real-world discontinuation of anticoagulants, however, is considerably higher. A recent observational study found discontinuation rates at 1 year to be approximately 60% for warfarin and 50% for DOACs. 31 Whereas some have found better persistence with rivaroxaban, [32] [33] [34] others found better persistence with warfarin. 13 We were unable to directly measure drug adherence, but there are several reasons why patients may adhere more to warfarin. First, a month's supply of rivaroxaban costs approximately $375, compared with $5 for a month's supply of warfarin.
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Although most commercial insurance plans cover rivaroxaban, patients facing higher co-pays and deductibles might economize by skipping doses or stopping their medication altogether. 36 Patients at risk of poor adherence with warfarin because they have trouble taking pills regularly may be particularly vulnerable to poor adherence with rivaroxaban, given the added dimension of cost. Second, the INR monitoring required for warfarin management may actually increase adherence, because providers review the importance of taking the drug at each encounter. One of rivaroxaban's chief advantages is the lack of routine therapeutic monitoring. Paradoxically, this convenience might render it less effective because less monitoring is associated with worse adherence. 37 For those patients who find maintaining a therapeutic INR on warfarin difficult as a result of poor adherence, physicians should not immediately assume that their adherence with rivaroxaban would be any better. It could be worse. In addition, whereas the half-life of warfarin is approximately 40 hours, the half-life of rivaroxaban is only 5 to 9 hours. Therefore, missing a dose of rivaroxaban is much more dangerous than missing a dose of warfarin. 7, 38 Although some health systems have implemented DOAC monitoring clinics, these remain uncommon, and the impact of such programs on clinical outcomes has not been adequately studied. We found that nearly a third of rivaroxaban patients who experienced thromboembolic events or major bleeding events were receiving inappropriately high drug doses. In contrast to trial settings, where study protocols dictate dosing, under real-world conditions, lack of familiarity may lead to inappropriate prescriptions, even in high-functioning health systems. Despite the rapid proliferation of DOACs, little is known about prescribing patterns of physicians, including their familiarity with common contraindications or dosing. 40 Our findings suggest that systems-based solutions, including pharmacist review or EHR prompts, may be necessary to avoid clinical events resulting from improper dosing or patient selection.
Our study had some limitations. Our inability to directly confirm drug adherence or persistence introduces the possibility of a patient not taking the medication appropriately, or at all, which could have affected the results. We were also unable to account for the influence of drug-drug interactions for rivaroxaban and warfarin patients. Moreover, although we had information on baseline thromboembolic risk, we did not have information on individual baseline bleeding risk. Because we excluded warfarin patients with fewer than 4 INRs, we may have excluded the least-adherent population of warfarin patients. Furthermore, our study is limited by our use of the Rosendaal method to estimate TTR because it does not designate the percentage of INRs that are above or below the therapeutic goal range. Consequently, having a TTR below the median does not necessarily correspond to being subtherapeutic. Not all patients in the study were managed by anticoagulation clinics within the CCHS, which may have introduced unmeasured variability in TTR by site. The study was also limited by the small number of observed outcome events, which limited the statistical power of the study, particularly for the stratified analysis. We were unable to measure thromboembolic or major bleeding events that occurred outside of the Cleveland Clinic Health System or those that were not coded. Therefore, it is possible that some patients experienced events that were unaccounted for in our analysis. Additionally, we were unable to rule out factors other than anticoagulation that may have contributed to thromboembolic or major bleeding events. Finally, because this study used data from a single institution, our findings may not be generalizable to the patient population at large.
Conclusions
Randomized trials provide information about the effects of drugs under ideal conditions, which do not reflect the conditions in the real world. Given the burden of stroke 41 as well as ever-increasing drug costs associated with some anticoagulants, 42 understanding the real-world experience of specific agents is imperative. Warfarin was associated with similar thromboembolic events compared with rivaroxaban in our study, and was equally safe, irrespective of therapeutic control. Individualized decision making, taking into account the nontherapeutic tradeoffs associated with these medications (eg, monitoring, half-life, cost) is warranted.
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